Clinical Trial Update: Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging [Phase 1]

View source ↗

Summary

Phase 1 biodistribution study of 89Zirconium-labelled GSK2398852 using PET imaging in amyloidosis; study TERMINATED with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• 89Zirconium-labelled GSK2398852 (89Zirconium-labelled GSK2398852)
• GSK2398852

Snippet

Sponsor: GlaxoSmithKline | Conditions: Amyloidosis | Phase 1 | Status: TERMINATED | Results posted: 2019-08-29